Doripenem May Increase Mortality Risk in Ventilator-Associated Pneumonia — Physician’s First Watch
Doripenem May Increase Mortality Risk in Ventilator-Associated Pneumonia
By Kristin J. Kelley
The antibacterial doripenem (marketed as Doribax) may pose an increased risk for death in patients with ventilator-associated pneumonia, the FDA warned. The drug's label will be changed to reflect these risks.
In a 3-year trial that was ended early, patients taking a 7-day course of doripenem had increased mortality risk and lower clinical cure rates than those given a 10-day course of imipenem and cilastatin.
The revisions will also include a warning against unapproved use of doripenem for any type of pneumonia.